4. How and when to take it
The usual dose of Klaribac is 250mg to 500mg twice a day.
The dose may be lower for children and if you have kidney problems.
If your doctor prescribes slow release or modified release tablets, the dose is 500mg once a day. These tablets release the medicine slowly, which means that 1 dose a day is enough.
Try to take your medicine at the same time every day.
Which drugs or supplements interact with Klaribac?
Klaribac interacts with several drugs because it reduces the activity of liver enzymes that breakdown many drugs. This leads to increased blood levels and side effects from the affected drugs. Examples of such interactions include
Klaribac increases blood levels of sildenafil (Viagra, Revatio), tadalafil (Cialis, Adcirca), vardenafil (Levitra), theophylline and carbamazepine (Tegretol), thereby increasing side effects of these drugs.
Ritonavir (Norvir) and atazanavir (Reyataz) increase blood levels of Klaribac while efavirenz (Sustiva), nevirapine (Viramune), rifampin, decrease blood levels of Klaribac.
Itraconazole (Sporanox) and saquinavir (Invirase) may increase blood levels of Klaribac while Klaribac increases blood levels or both drugs.
The occurrence of abnormal heart beats may increase when Klaribac is combined with drugs that affect heart beat (for example, amiodarone , quinidine , and disopyramide).
Storage And Handling
BIAXIN Filmtab (Klaribac tablets, USP) is supplied as yellow oval film-coated tablets in the following packaging sizes: 250 mg tablets: (imprinted in blue with the “a” logo and KT)
Bottles of 60 (NDC 0074-3368-60) and unit dose strip packages of 100 (NDC 0074-3368-11).
Store BIAXIN Filmtab 250 mg at controlled room temperature 15° to 30°C (59° to 86°F) in a well-closed container. Protect from light.
500 mg tablets: (debossed with the “a” logo on one side and KL on the opposite side)
Bottles of 60 (NDC 0074-2586-60) and unit dose strip packages of 100 (NDC 0074-2586-11).
Store BIAXIN Filmtab 500 mg at controlled room temperature 20° to 25°C (68° to 77°F) in a well-closed container.
BIAXIN XL Filmtab (Klaribac extended-release tablets) is supplied as yellow oval film-coated tablets in the following packaging sizes:
500 mg tablets: (debossed with the “a” logo and KJ)
Bottles of 60 (NDC 0074-3165-60), unit dose strip packages of 100 (NDC 0074-3165-11), and BIAXIN XL PAC carton of 4 blister packages 14 tablets each (NDC 0074-3165-41).
Store BIAXIN XL Filmtab at 20° to 25°C (68° to 77°F). Excursions permitted to 15° to 30°C (59° to 86°F).
BIAXIN Granules (Klaribac for oral suspension, USP) is supplied as white to off-white granules in the following strengths and sizes:
Store BIAXIN Granules below 25°C (77°F) in a well-closed container. Do not refrigerate the reconstituted BIAXIN granules.
BIAXIN Filmtab 250 mg and 500 mg and BIAXIN XL Filmtab 500 mg Mfd. by AbbVie LTD, Barceloneta, PR 00617. BIAXIN Granules, 125 mg/5 mL and 250 mg/5 mL Mfd. by AbbVie Inc., North Chicago, IL 60064 For AbbVie Inc., North Chicago, IL 60064, U.S.A. Revised: Nov 2018.
Common Side Effects of Klaribac
Some common side effects of Klaribac include:
- Stomach pain
- Change in taste
Klaribac, like other macrolide antibiotics, has been linked to a low rate of acute, transient and usually asymptomatic elevations in serum aminotransferase levels which occur in 1% to 2% of patients treated for short periods and a somewhat higher proportion of patients given Klaribac long term. Asymptomatic elevations in serum enzymes are particularly common among elderly patients given higher doses of Klaribac.
Klaribac can also cause acute, clinically apparent liver injury with jaundice, which is estimated to occur in 3.8 per 100,000 prescriptions. The liver injury usually appears within the first 1 to 3 weeks after initiation of treatment and can arise after Klaribac is stopped. The pattern of liver enzyme elevations varies, but the resulting hepatitis is often cholestatic and can be prolonged (Case 1). Allergic signs and symptoms have not been consistently reported. While cholestatic hepatitis is most typical of Klaribac induced liver injury, rare cases with hepatocellular injury and abrupt onset have been described. These hepatocellular cases are more likely to be severe and can result in acute liver failure. However, in most instances, recovery occurs within 4 to 8 weeks of withdrawal of the medication. The typical latency, clinical pattern and course of the cholestatic hepatitis due to Klaribac resembles that of the other macrolide antibiotics.
Likelihood score: B (highly likely cause of clinically apparent liver injury).
Pregnancy Category C
Klaribac should not be used in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus .
Four teratogenicity studies in rats (three with oral doses and one with intravenous doses up to 160 mg/kg/day administered during the period of major organogenesis) and two in rabbits at oral doses up to 125 mg/kg/day (approximately twice the recommended maximum human dose based on mg/m²) or intravenous doses of 30 mg/kg/day administered during gestation days 6 to 18 failed to demonstrate any teratogenicity from Klaribac. Two additional oral studies in a different rat strain at similar doses and similar conditions demonstrated a low incidence of cardiovascular anomalies at doses of 150 mg/kg/day administered during gestation days 6 to 15.
Plasma levels after 150 mg/kg/day were twice the human serum levels. Four studies in mice revealed a variable incidence of cleft palate following oral doses of 1000 mg/kg/day (2 and 4 times the recommended maximum human dose based on mg/m², respectively) during gestation days 6 to 15. Cleft palate was also seen at 500 mg/kg/day. The 1000 mg/kg/day exposure resulted in plasma levels 17 times the human serum levels. In monkeys, an oral dose of 70 mg/kg/day produced fetal growth retardation at plasma levels that were twice the human serum levels.
Getting the most from your treatment
- Some people develop thrush (redness and itchiness in the mouth or vagina) after taking a course of antibiotics. If this happens to you, speak with your doctor or pharmacist for advice about how to treat it.
- This antibiotic may stop the oral typhoid vaccine from working. If you are having any vaccinations, make sure the person treating you knows that you are taking this medicine.
- If you are taking a 'statin' medicine for high cholesterol your doctor may advise you to stop taking the statin whilst being treated with Klaribac. Ask your doctor or pharmacist if you are unsure.
- If you are having an operation or dental treatment, tell the person carrying out the treatment that you are taking Klaribac.
- If you buy any medicines, check with a pharmacist that they are suitable to take with this antibiotic.
- If you still feel unwell after completing your course of the antibiotic, make another appointment to see your doctor.
What if I take too much?
Taking an extra dose of Klaribac by accident is unlikely to harm you or your child.
It may give you temporary side effects, like stomach pain, feeling and being sick, and diarrhoea.
Talk to your pharmacist or doctor if you're worried or get severe side effects, or if you or your child accidentally take more than 1 extra dose.
Like all medicines, Klaribac can cause side effects, although not everyone gets them.
Following administration of Klaribac (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and Cmax increased 177% and 187% respectively compared to administration of saquinavir alone. Klaribac AUC and Cmax increased 45% and 39% respectively, whereas the 14–OH Klaribac AUC and Cmax decreased 24% and 34% respectively, compared to administration with Klaribac alone.
What is Klaribac used for?
Klaribac is used to treat infections caused bacteria, including the following:
▪️ Chest infections such as bronchitis, pneumonia.
▪️ Infections of the nasal passages, sinuses or throat such as sinusitis, pharyngitis
▪️ Skin or soft tissue infections, such as cellulitis, folliculitis or erysipelas.
▪️ Eradicating Helicobacter pylori bacteria from the gut.
▪️ to prevent whooping cough in people who haven't been vaccinated against whooping cough and who are in close contact with someone who has it.
Rated Klaribac for Skin or Soft Tissue Infection Report
I've just finished the course of seven days 2 x 500mg Klaribac and I only experienced a horrific bitter taste in my mouth & extreme tiredness, no other side effects. I was given this antibiotic after trying Flucloxicillin & Erithromycin & the infection is still there. I don't know if I'd recommend it but I found the bitter taste very nasty. I've finished the course and it's still there. Food tastes like ?? and I'd wake up in the night with it, it was that bad!
What is Klaribac?
Klaribac is a macrolide antibiotic that fights bacteria in your body.
Klaribac is used to treat many different types of bacterial infections affecting the skin and respiratory system.
Klaribac is also used together with other medicines to treat stomach ulcers caused by Helicobacter pylori.